{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:34:21Z","timestamp":1772768061402,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","award":["Plateforme DRUGS-SAFE"],"award-info":[{"award-number":["Plateforme DRUGS-SAFE"]}],"id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40264-020-00936-1","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T06:02:36Z","timestamp":1587189756000},"page":"767-774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7873-5483","authenticated-orcid":false,"given":"Antoine","family":"Pariente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Labat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohann","family":"Mansiaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"B\u00e9gaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Faillie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"L\u00e9tinier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"key":"936_CR1","unstructured":"European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of meeting 3\u20135 September 2012. Sitagliptin\u2014Signal of rhabdomyolysis. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Minutes\/2012\/10\/WC500133303.pdf. Accessed 24 Nov 2019."},{"key":"936_CR2","unstructured":"European Medicines Agency. PRAC recommendations on signals. Adopted at the PRAC meeting of 10\u201313 June 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/PRAC_recommendation_on_signal\/2014\/07\/WC500169486.pdf. Accessed 24 Nov 2019."},{"key":"936_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1464-5491.2011.03502.x","volume":"29","author":"R Bhome","year":"2012","unstructured":"Bhome R, Penn H. Myopathy precipitated by a sitagliptin\u2013atorvastatin drug interaction. Diabet Med. 2012;29:693\u20134.","journal-title":"Diabet Med."},{"key":"936_CR4","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/j.1464-5491.2008.02536.x","volume":"25","author":"DP Kao","year":"2008","unstructured":"Kao DP, Kohrt HE, Kugler J. Renal failure and myopathy associated with sitagliptin and simvastatin use. Diabet Med. 2008;25:1229\u201330.","journal-title":"Diabet Med."},{"key":"936_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1592\/phco.29.3.352","volume":"29","author":"R DiGregorio","year":"2010","unstructured":"DiGregorio R, Pasikhova Y. Rhabdomyolysis caused by a potential sitagliptin\u2013lovastatin interaction. Pharmacotherapy. 2010;29:352\u20136.","journal-title":"Pharmacotherapy."},{"key":"936_CR6","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.2337\/dc16-1822","volume":"40","author":"V Labat","year":"2017","unstructured":"Labat V, Arnaud M, Miremont-Salam\u00e9 G, Salvo F, B\u00e9gaud B, Pariente A. Risk of myopathy associated with DPP-4 inhibitors in combination with statins: a disproportionality analysis using data from the WHO and French Spontaneous Reporting Databases. Diabetes Care. 2017;40:e27\u20139.","journal-title":"Diabetes Care."},{"key":"936_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01378-7","author":"IC Antonazzo","year":"2019","unstructured":"Antonazzo IC, Poluzzi E, Forcesi E, Salvo F, Pariente A, Marchesini G, et al. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug\u2013drug interactions through the FDA adverse event reporting system. Acta Diabetol. 2019. https:\/\/doi.org\/10.1007\/s00592-019-01378-7.","journal-title":"Acta Diabetol."},{"key":"936_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","volume":"33","author":"Y Chatzizisis","year":"2010","unstructured":"Chatzizisis Y, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33:171\u201387.","journal-title":"Drug Saf."},{"key":"936_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/VHRM.S79198","volume":"11","author":"WH Ramadan","year":"2015","unstructured":"Ramadan WH, Kabbara WK. Sitagliptin\/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia\u2014a review of its characteristics. Vasc Health Risk Manag. 2015;11:125\u201332.","journal-title":"Vasc Health Risk Manag"},{"key":"936_CR10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","volume":"58","author":"P Tuppin","year":"2010","unstructured":"Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merliere Y. French national health insurance information system and the permanent beneficiaries\u2019 sample. Rev Epidemiol Sante Publique. 2010;58:286\u201390.","journal-title":"Rev Epidemiol Sante Publique."},{"key":"936_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3917\/pos.403.0213","volume":"40","author":"L De Roquefeuil","year":"2009","unstructured":"De Roquefeuil L, Neumann A, Merli\u00e8re Y. The Echantillon g\u00e9n\u00e9raliste de b\u00e9n\u00e9ficiaires: representativeness, scope and limits. Pratiques Organ Soins. 2009;40:213\u201323.","journal-title":"Pratiques Organ Soins."},{"key":"936_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2110-5820-3-8","volume":"3","author":"Esmael El-Abdellati","year":"2013","unstructured":"El-Abdellati Esmael, et al. An observational study on rhabdomyolysis in the intensive care unit. Exploring its risk factors and main complication: acute kidney injury. Ann Intensive Care. 2013;3:8.","journal-title":"Ann Intensive Care"},{"key":"936_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13054-016-1314-5","volume":"20","author":"LO Chavez","year":"2016","unstructured":"Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20:135.","journal-title":"Crit Care."},{"key":"936_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40264-016-0473-2","volume":"40","author":"SJ Duncan","year":"2017","unstructured":"Duncan SJ, Howden CW. Proton pump inhibitors and risk of rhabdomyolysis. Drug Saf. 2017;40:61\u20134.","journal-title":"Drug Saf."},{"key":"936_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/bcp.13515","volume":"84","author":"T Deljehier","year":"2018","unstructured":"Deljehier T, Pariente A, Miremont-Salam\u00e9 G, Haramburu F, Nguyen L, Rubin S, et al. Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions. Br J Clin Pharmacol. 2018;84:1057\u201363.","journal-title":"Br J Clin Pharmacol."},{"key":"936_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/vhrm.2007.3.2.203","volume":"3","author":"B Gallwitz","year":"2007","unstructured":"Gallwitz B. Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vasc Health Risk Manag. 2007;3:203\u201310.","journal-title":"Vasc Health Risk Manag."},{"key":"936_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2165\/11532980-000000000-00000","volume":"49","author":"AJ Scheen","year":"2010","unstructured":"Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug\u2013drug interactions. Clin Pharmacokinet. 2010;49:573\u201388.","journal-title":"Clin Pharmacokinet."},{"key":"936_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"PJ Neuvonen","year":"2006","unstructured":"Neuvonen PJ. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565\u201381.","journal-title":"Clin Pharmacol Ther."},{"key":"936_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejim.2015.01.002","volume":"26","author":"P Magni","year":"2015","unstructured":"Magni P, Macchi C, Morlotti B, Sirtori CR, Ruscica M. Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Eur J Intern Med. 2015;26:82\u20138.","journal-title":"Eur J Intern Med."},{"key":"936_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0091270008330983","volume":"49","author":"AJ Bergman","year":"2009","unstructured":"Bergman AJ, Cote J, Maes A, Zhao JJ, Roadcap BA, Sun L, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol. 2009;49:483\u20138.","journal-title":"J Clin Pharmacol."},{"key":"936_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/clpt.2014.121","volume":"96","author":"A Alfirevic","year":"2014","unstructured":"Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014;96:470\u20136.","journal-title":"Clin Pharmacol Ther."},{"key":"936_CR22","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Ochoa EO, Llanos P, Lanner JT. The underlying mechanisms of diabetic myopathy. J Diabetes Res. 2017. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5697129\/.","DOI":"10.1155\/2017\/7485738"},{"key":"936_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40264-016-0399-8","volume":"39","author":"A Mascolo","year":"2016","unstructured":"Mascolo A, Rafaniello C, Sportiello L, Sessa M, Cimmaruta D, Rossi F, et al. Dipeptidyl peptidase (DPP)-4 inhibitor-induced arthritis\/arthralgia: a review of clinical cases. Drug Saf. 2016;39:401\u20137.","journal-title":"Drug Saf."},{"key":"936_CR24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/pds.3503","volume":"22","author":"M Tarapu\u00e9s","year":"2013","unstructured":"Tarapu\u00e9s M, Cereza G, Figueras A. Association of musculoskeletal complaints and gliptin use: review of spontaneous reports. Pharmacoepidemiol Drug Saf. 2013;22:1115\u20138.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"936_CR25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jamda.2016.04.016","volume":"17","author":"MR Rizzo","year":"2016","unstructured":"Rizzo MR, Barbieri M, Fava I, Desiderio M, Coppola C, Marfella R, et al. Sarcopenia in elderly diabetic patients: role of dipeptidyl peptidase 4 inhibitors. J Am Med Direct Assoc. 2016;17:896\u2013901.","journal-title":"J Am Med Direct Assoc"},{"key":"936_CR26","doi-asserted-by":"publisher","first-page":"e2957","DOI":"10.1002\/dmrr.2957","volume":"34","author":"R Bouchi","year":"2018","unstructured":"Bouchi R, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, et al. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. Diabetes Metab Res Rev. 2018;34:e2957.","journal-title":"Diabetes Metab Res Rev."},{"key":"936_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/9781118820186.ch20","volume-title":"Mann\u2019s pharmacovigilance","author":"A Bate","year":"2014","unstructured":"Bate A, Pariente A, Hauben M, Begaud B. Quantitative signal detection and analysis in pharmacovigilance. In: Andrews EB, Moore N, editors. Mann\u2019s pharmacovigilance. 3rd ed. Chichester: Wiley; 2014. p. 331\u201355.","edition":"3"},{"key":"936_CR28","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30:891\u20138.","journal-title":"Drug Saf."},{"key":"936_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37:283\u201394.","journal-title":"Drug Saf."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00936-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00936-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00936-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T23:11:08Z","timestamp":1618701068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00936-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["936"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00936-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,18]]},"assertion":[{"value":"18 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no further conflict of interest to declare. Louis L\u00e9tinier is a co-founder of Synapse Medicine (). Synapse Medicine played no role in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"V.L. was a beneficiary of a specific grant from the <i>Fondation pour la Recherche M\u00e9dicale<\/i> (FRM). A.P. is the coordinator of the DRUGS Systematised Assessment in real-liFe Environment (DRUGS-SAFE) program funded by the <i>Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9<\/i> (ANSM). The present study was included in the DRUGS-SAFE program. This program aims at providing an integrated system allowing the concomitant monitoring of drug use and safety in France. The potential impact of drugs, frailty of populations and seriousness of risks drive the research program. The funding sources played no role in the design and interpretation of this study. This publication represents the views of the authors and does not necessarily represent the opinion of ANSM or the FRM.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Publicly sharing EGB data is forbidden by law according to The French national data protection agency (<i>Commission Nationale de l\u2019Informatique et des Libert\u00e9s<\/i>, CNIL); regulatory decisions AT\/CPZ\/SVT\/JB\/DP\/CR05222O of June 14, 2005 and DP\/CR071761 of August 28, 2007. To request data access please contact The National Institute for Health Data (Institut National des Donn\u00e9es de Sant\u00e9, INDS).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}}]}}